ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / VKTX / dividends
PBLS (47) ACAD (49) IRON (54) AMLX (39) ⌘ Pro Terminal →

Viking Therapeutics Inc. (VKTX) Dividend Safety Gauge & 10-Year DRIP Compounder

$26.83 -1.65% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $26.70

Viking Therapeutics Inc. (VKTX) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $3.48B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VKTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VKTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Viking Therapeutics Inc. (NASDAQ: VKTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $26.83 (-1.65% 1D, market cap $3.48B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, VKTX ranks #399 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VKTX compare to PBLS and ACAD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VKTX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PBLS (Parabilis Medicines Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.45B) and ACAD (ACADIA Pharmaceuticals Inc.) posts a D grade (49/100 RQD, P/E 9.1x, ROIC 7.9%, cap $3.55B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while ACAD leads on capital efficiency (7.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VKTX?
▼

Per VKTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001607678), Viking Therapeutics Inc. generated $1.10B in revenue (+160.6% YoY), -$359.6M in net income, and -$278.7M in free cash flow against $715.7M in total assets and $34.5M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $26.70 (-0.49%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510043
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C-
Cash (8)Whales (6)SEC (16)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-6.7% Base Target
$45 Bull$25 Base$20 Bear
📬 FREE VKTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VKTX)Realized 20D OHLCV Swing Band: ±12%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY VKTX SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (37% of score)

Altman Z-Score 24.02 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (19% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
35
Grade E$25.47+3.6% Next Q
Q2 (-2Q)
38
Grade E$26.38-3.9% Next Q
Q3 (-1Q)
40
Grade D$25.36+5.8% Next Q
Current
43
Grade D-$26.83-6.7% Hist 90D α
Trajectory: E (35) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VKTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VKTX currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($30.11) and Max Pain ($28.17) forces dealer call-delta covering toward $45.31.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VKTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VKTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (9.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $23,892

Est. Year-10 Shareholder Yield: $143/yr
$10.9K
Yr 1
$11.9K
Yr 2
$13.0K
Yr 3
$14.2K
Yr 4
$15.5K
Yr 5
$16.9K
Yr 6
$18.4K
Yr 7
$20.1K
Yr 8
$21.9K
Yr 9
$23.9K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VKTX)

  • ✓Walkthrough of VKTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VKTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -15.52%📐 HORIZONTAL RANGE
2026-11-03O $26.86H $27.28L $26.83C $26.83VOL 5.14M
RES: $43.27SUP: $22.82SMA50: $30.11SMA200: $32.31
$44.45$38.86$33.27$27.68$22.08RES $43.27SUP $22.82$26.832026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VKTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VKTX Butterfly Map → + Track VKTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
27.0%/yr Implied 5Y Growth

vs. +160.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VKTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VKTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VKTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VKTX)

Health Care Rank #399 of 1015 ⚔️ PBLS vs VKTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VKTX vs. PBLS, ACAD, IRON, AMLX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Viking Therapeutics Inc. (VKTX) ranks #399 by composite RQD confidence (43/100, grade D-) and #193 by equity capitalization ($3.48B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while ACAD leads on capital efficiency and profitability with 7.9% ROIC and 91.7% gross margin. IRON currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with VKTX at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VKTX ACTIVE
Viking Therapeutics Inc.
D- 43/100 — — -35.0% -1.65% $3.48B Benchmark Subject
PBLS
Parabilis Medicines Inc.
D 47/100 — — — -3.78% $3.45B /pbls-vs-vktx →
ACAD
ACADIA Pharmaceuticals Inc.
D 49/100 9.1x 91.7% 7.9% -0.58% $3.55B /acad-vs-vktx →
IRON
Disc Medicine Inc.
D+ 54/100 — — -27.5% -2.75% $3.59B /iron-vs-vktx →
AMLX
Amylyx Pharmaceuticals Inc.
D- 39/100 — — -35.0% -2.84% $3.62B /amlx-vs-vktx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001607678 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Viking Therapeutics Inc. (VKTX) reported GAAP revenue of $1.10B (+160.6% vs. FY2024 revenue of $422.6M , and +290.1% cumulative change since FY2023) , GAAP net income of -$359.6M, operating cash flow of -$278.7M, and free cash flow of -$278.7M (-217.4% YoY). On the balance sheet, VKTX closed FY2025 with $715.7M in total assets against $34.5M in total debt (Altman Z-Score: 24.02, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.10B -$359.6M -$278.7M -$278.7M $715.7M $34.5M
FY2024 (FY) 2024-12-31 $422.6M -$110.0M -$87.8M -$87.8M $908.3M $12.6M
FY2023 (FY) 2023-12-31 $282.3M -$85.9M -$73.4M -$73.4M $1.86B $434.5M

3. VKTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VKTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Viking Therapeutics Inc. (NASDAQ: VKTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $26.83 (-1.65% 1D, market cap $3.48B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, VKTX ranks #399 in composite RQD confidence.

How does VKTX compare to PBLS and ACAD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VKTX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PBLS (Parabilis Medicines Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.45B) and ACAD (ACADIA Pharmaceuticals Inc.) posts a D grade (49/100 RQD, P/E 9.1x, ROIC 7.9%, cap $3.55B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while ACAD leads on capital efficiency (7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VKTX?

Per VKTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001607678), Viking Therapeutics Inc. generated $1.10B in revenue (+160.6% YoY), -$359.6M in net income, and -$278.7M in free cash flow against $715.7M in total assets and $34.5M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VKTX trading relative to its 50-day, 200-day, and 52-week technical levels?

VKTX last traded at $26.83 (-1.65% on volume of 4,433,891 shares), positioning the stock -10.89% below its 50-day simple moving average ($30.11) and -16.96% below its 200-day simple moving average ($32.31). Across its 52-week range of $23.82 to $43.15, VKTX sits at the 15.6% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($23.61 to $30.05).

Direct Sub-Reports: VKTX RQD Cockpit VKTX 12M Forecast VKTX Earnings & Move VKTX Dividends & DRIP VKTX Insiders & 13F VKTX Whale Options VKTX Profit Sankey VKTX News & Why
ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ SEC XBRL & RQD VERIFIED

VKTX — Viking Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Viking Therapeutics Inc. (VKTX) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $26.83 (-1.65% 1D, market capitalization $3.48B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -8.25%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (16/20): Incorporates a 0.91x equity beta, Altman Z-Score of 24.02, Piotroski F-Score of 5/9, and Debt/Equity of 0.05x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Viking Therapeutics Inc. (VKTX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). Its market capitalization is $3.4B (per the company profile). Reported revenue is — in each period shown ().

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Viking Therapeutics Inc. (VKTX) reported $1.10B in annual revenue (up from $422.6M in FY2024, +160.6% YoY) and -$359.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($282.3M revenue, -$85.9M net income) through FY2025, VKTX scaled operating cash flow to -$278.7M and free cash flow to -$278.7M, backed by $715.7M in total assets against $34.5M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 43/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of -8.25% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $23.82 – $43.15 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 0.91x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), VKTX carries a macro regime beta of 0.91 and gross margin of —.

  • Key Question #1: Can VKTX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.10B and free cash flow of -$278.7M, how will capital allocation balance growth reinvestment against $34.5M in total debt?
  • Key Question #3: How sensitive is VKTX's 35.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.91x)?

VKTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Viking Therapeutics Inc. (VKTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VKTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VKTX Bull vs. Bear Conversation Board — What's Your Call at $26.83?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VKTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VKTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $36.01 (+32.0%)
📌 Pinned Debate

The balance sheet scores 16/20 with Altman Z 24.02 and Debt/Equity 0.05, and cash rose to $165.8M in FY 2025 against $34.5M of debt.

Long VKTX at $27.28 targeting $36.01. The balance sheet scores 16/20 with Altman Z 24.02 and Debt/Equity 0.05, and cash rose to $165.8M in FY 2025 against $34.5M of debt.. Institutional whale score is 6/20 and the risk/reward vs. the $23.82 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@MultipleCompression Fair point on 35.0x forward P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $22.10 (-19.0%)
Spot @ $27.28

ROIC of -35%, FCF yield of -8.25%, and EPS TTM of -2.86 show continued losses and cash burn, with FY 2025 free cash flow at -$278.7M.

I respect the product at Viking Therapeutics Inc., but the stock at $27.28 is a different story. ROIC of -35%, FCF yield of -8.25%, and EPS TTM of -2.86 show continued losses and cash burn, with FY 2025 free cash flow at -$278.7M.. FCF yield is -8.25% and RQD sits at 43/100 (D-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%